Health Canada open data (page 51)
Health Canada publishes 2,987 open datasets on CanQuery: 58 with live tables. Preview tables, export CSV and follow original downloads.
- Datasets
- 2987
- Queryable datasets
- 58
- Mappable datasets
- 0
Datasets
- Revised Guidance Document: Acetaminophen Labelling Standard
- Prohibitions related to scientific research and clinical applications
- Prohibitions related to Surrogacy
- Consent to Use Human Reproductive Material and In Vitro Embryos
- Toward a strengthened Assisted Human Reproduction Act
- Reimbursing a sperm or ova (egg) donor or a surrogate for expenditures related to donation or surrogacy
- Reporting a complaint for the Assisted Human Reproduction Act
- Inspection approach for blood establishments (POL-0039)
- Prohibitions related to Purchasing Reproductive Material and Purchasing or Selling In Vitro Embryos
- Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products
- Notice: Guidance Document - Data Requirements for Safety and Effectiveness of Subsequent Entry Inhaled Corticosteroid Products Used for the Treatment of Asthma
- Guidance Document - Human-Use Antiseptic Drugs
- Mandatory reporting of serious adverse drug reactions and medical device incidents by hospitals - Overview
- Guidance Document for Source Establishments - Reporting Adverse Reactions to Human Cells, Tissues and Organs
- Donating and using third-party sperm or ova (eggs) for assisted human reproduction
- Compliance and Enforcement: Assisted Human Reproduction
- Blood for transfusion or for use in the manufacture of a drug
- Myths and facts - plasma donation
- Plasma Donation in Canada
- Blood Establishment Licensing Application Form and Instructions - (FRM-0354)
- Blood Establishment Registration Application: Form and Instructions - (FRM-0353)
- Guidance Document: Blood Regulations
- COVID-19: Readiness criteria and indicators for easing restrictive public health measures
- National Advisory Committee on Immunization (NACI): Summary of extended dose interval statement of April 7, 2021
- Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply
- Vaccines for COVID-19: What to expect at your vaccination
- Government of Canada establishes Critical Drug Reserve to bolster Canada’s supply of drugs used to treat COVID-19
- Interim Order No. 2 Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19
- Government of Canada announces funding to help reduce stigma and support families affected by the overdose crisis
- COVID-19 clinical trials IO and clinical trials records retention: Consultation report
- Explanatory note on new interim order to advance COVID-19 clinical trials
- COVID-19: Application of the Quarantine Act Border Measures (ArriveCAN 2) (July 2020)
- 2021–22 Departmental Plan: Health Canada
- Federal actions on opioids to date
- Helping people who use substances during the COVID-19 pandemic
- Canada-Northwest Territories Bilateral Agreement for Pan-Canadian Virtual Care Priorities in Response to COVID-19
- Guidance on applications for drug clinical trials under the interim order: Overview
- Interim Order No. 2 respecting clinical trials for medical devices and drugs relating to COVID-19: Notice
- Filing a drug or device marketing complaint: How to report an incident
- Health product advertising incidents related to COVID-19: COVID-19 advertising incidents
- Priority COVID-19 test applications: Notice to manufacturers, importers and distributors
- Management of clinical trials during the COVID-19 pandemic: Notice to clinical trial sponsors
- Applications for COVID-19 drug and medical device clinical trials under the interim order: Notice of updated guidance documents
- Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) - Summary
- Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100)
- Canada-Ontario Bilateral Agreement for Pan-Canadian Virtual Care Priorities in Response to COVID-19
- Canada-Prince Edward Island Bilateral Agreement for Pan-Canadian Virtual Care Priorities in Response to COVID-19
- Canada-Alberta Bilateral Agreement for Pan-Canadian Virtual Care Priorities in Response to COVID-19
- Canada - Yukon Bilateral Agreement for Pan-Canadian Virtual Care Priorities in Response to COVID-19
- Canada-Saskatchewan Bilateral Agreement for Pan-Canadian Virtual Care Priorities in Response to COVID-19